Identification

Name
Prednisolone
Accession Number
DB00860  (APRD00197)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]

Structure
Thumb
Synonyms
  • (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
  • 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
  • 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
  • 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
  • delta-dehydrocortisol
  • delta-dehydrohydrocortisone
  • delta-hydrocortisone
  • delta(1)-Dehydrocortisol
  • delta(1)-Dehydrohydrocortisone
  • delta(1)-Hydrocortisone
  • Hydroretrocortine
  • Metacortandralone
  • PRDL
  • Prednisolona
  • Prednisolonum
External IDs
NSC-9120 / NSC-9900
Product Ingredients
IngredientUNIICASInChI Key
Prednisolone 21-phosphate752SY38R6C302-25-0JDOZJEUDSLGTLU-VWUMJDOOSA-N
Prednisolone acetate8B2807733D52-21-1LRJOMUJRLNCICJ-JZYPGELDSA-N
Prednisolone sodium phosphateIV021NXA9J125-02-0VJZLQIPZNBPASX-OJJGEMKLSA-L
prednisolone sodium succinate8223RR9DWF1715-33-9FKKAEMQFOIDZNY-CODXZCKSSA-M
Prednisolone tebutate1V7A1U282K7681-14-3HUMXXHTVHHLNRO-KAJVQRHHSA-N
Prednisolone tertiary butylacetateNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%Suspension1 %OphthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%Suspension1 %OphthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-PredSuspension15 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%Liquid10 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%Solution1 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase MildLiquid.125 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%Liquid1.25 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%Solution / drops0.5 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Novo-prednisolone 5mgTablet5 mgOralNovopharm Limited1967-12-312005-08-10Canada
OmnipredSuspension10 mg/mLOphthalmicAlcon, Inc.2007-11-06Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredTablet5 mg/5mgOralLaser Pharmaceuticals Llc2008-10-01Not applicableUs16477 0505 01 nlmimage10 851b42ca
MillipredSolution10 mg/5mLOralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredSolution10 mg/5mLOralLaser Pharmaceuticals Llc2009-07-01Not applicableUs
MillipredTablet5 mg/1OralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
OrapredSolution15 mg/5mLOralShionogi2000-12-142016-02-22Us
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2003-03-26Not applicableUs
PrednisoloneSolution15 mg/5mLOralAidarex Pharmaceuticals LLC2003-02-27Not applicableUs
PrednisoloneSyrup15 mg/5mLOralEthex Corporation2004-05-10Not applicableUs
PrednisoloneSolution15 mg/5mLOralPreferreed Pharmaceuticals Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralApotheca, Inc.2003-02-27Not applicableUs
International/Other Brands
Ak-Pred / Decortin H / Delta-Cortef / Deltacortril / Hydeltra / Hydeltra-TBA / Hydeltrasol / Inflamase / Key-Pred / Klismacort / Meticortelone / Panafcortelone / Precortalon / Predonine / Prelone / Solone / Sterolone / Ultracortenol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicA S Medication Solutions1961-10-012017-06-20Us
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicAllergan1987-01-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicPhysicians Total Care, Inc.1961-10-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicA S Medication Solutions1987-01-012017-06-20Us
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicAllergan1961-10-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicPhysicians Total Care, Inc.2012-03-04Not applicableUs
Blephamide Oph OntPrednisolone acetate (0.2 %) + Sulfacetamide sodium (10 %)OintmentOphthalmicAllergan1974-12-31Not applicableCanada
Blephamide Opht SuspensionPrednisolone acetate (0.2 %) + Sulfacetamide sodium (10 %)Solution / dropsOphthalmicAllergan1989-12-31Not applicableCanada
Dioptimyd OintmentPrednisolone acetate (5 mg) + Sulfacetamide sodium (100 mg)OintmentOphthalmic; TopicalEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Metimyd Oph SusPrednisolone acetate (5 mg) + Sulfacetamide sodium (100 mg)SuspensionOphthalmicSchering Plough1956-12-311999-07-22Canada
Categories
UNII
9PHQ9Y1OLM
CAS number
50-24-8
Weight
Average: 360.444
Monoisotopic: 360.193674006
Chemical Formula
C21H28O5
InChI Key
OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.

Structured Indications
Pharmacodynamics

Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

Mechanism of action

Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.

Volume of distribution
Not Available
Protein binding

Very high (>90%)

Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of elimination
Not Available
Half life

2-3 hours

Clearance
Not Available
Toxicity

LD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Prednisone Action PathwayDrug action
Prednisolone Action PathwayDrug action
Prednisone Metabolism PathwayDrug metabolism
Prednisolone Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Prednisolone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisolone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prednisolone.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Prednisolone.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisolone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Prednisolone.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prednisolone.Approved, Withdrawn
AldesleukinPrednisolone may decrease the antineoplastic activities of Aldesleukin.Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Prednisolone.Investigational
AlmasilateThe bioavailability of Prednisolone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prednisolone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.Approved
AloglutamolThe bioavailability of Prednisolone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Prednisolone.Experimental
AluminiumThe bioavailability of Prednisolone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Prednisolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Prednisolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.Approved
AmiodaroneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BPrednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prednisolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednisolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisolone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prednisolone.Approved, Investigational
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Prednisolone resulting in a loss in efficacy.Approved, Investigational
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prednisolone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Prednisolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Prednisolone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Prednisolone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Prednisolone.Experimental
BendroflumethiazidePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Prednisolone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednisolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisolone.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Prednisolone.Experimental
Bismuth SubcitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Prednisolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prednisolone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prednisolone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisolone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prednisolone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Prednisolone.Experimental
BumetanidePrednisolone may increase the hypokalemic activities of Bumetanide.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisolone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prednisolone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Prednisolone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisolone.Approved
Capromab pendetidePrednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Prednisolone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisolone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisolone.Approved, Investigational
CeritinibThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Prednisolone.Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prednisolone.Approved, Vet Approved
ChlorothiazidePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prednisolone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.Approved
ChlorthalidonePrednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisolone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Prednisolone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisolone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prednisolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Prednisolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Prednisolone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prednisolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Prednisolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednisolone.Investigational
CyclopenthiazidePrednisolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Prednisolone.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Prednisolone.Investigational
DabrafenibThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Prednisolone can be increased when it is combined with Daidzein.Experimental
DanazolPrednisolone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prednisolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Prednisolone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Prednisolone.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prednisolone.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prednisolone.Approved, Vet Approved
DienestrolThe serum concentration of Prednisolone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Prednisolone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Prednisolone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prednisolone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Prednisolone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Prednisolone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Prednisolone.Experimental
DihydroergotamineThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteronePrednisolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Prednisolone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Distigmine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Prednisolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednisolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Prednisolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Prednisolone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisolone.Approved
EquolThe serum concentration of Prednisolone can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prednisolone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prednisolone.Approved
ErythromycinThe metabolism of Prednisolone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Prednisolone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Prednisolone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.Approved
Etacrynic acidPrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Prednisolone.Experimental
Ethinyl EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisolone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prednisolone.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisolone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Prednisolone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Prednisolone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prednisolone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Prednisolone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prednisolone.Experimental
FingolimodPrednisolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prednisolone.Approved, Withdrawn
FluconazoleThe metabolism of Prednisolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prednisolone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Prednisolone.Experimental
FluoxymesteronePrednisolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisolone.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Prednisolone.Approved
FluvoxamineThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prednisolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prednisolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Prednisolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prednisolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prednisolone is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Prednisolone.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.Approved, Investigational
GLPG-0492Prednisolone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednisolone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Prednisolone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisolone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prednisolone.Experimental
HexestrolThe serum concentration of Prednisolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednisolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prednisolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.Approved, Investigational
HydrochlorothiazidePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Prednisolone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednisolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prednisolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prednisolone.Approved
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Prednisolone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Prednisolone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisolone.Approved
IndapamidePrednisolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Prednisolone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Prednisolone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Prednisolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednisolone.Withdrawn
IsradipineThe metabolism of Prednisolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prednisolone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisolone.Experimental
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Prednisolone.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisolone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisolone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Prednisolone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Prednisolone.Experimental
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisolone.Approved, Investigational
LovastatinThe metabolism of Prednisolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisolone.Approved, Investigational
LuliconazoleThe serum concentration of Prednisolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Prednisolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisolone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Prednisolone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisolone.Approved
Magnesium silicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisolone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.Approved
MesterolonePrednisolone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Prednisolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Prednisolone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.Approved
MethallenestrilThe serum concentration of Prednisolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Methanesulfonyl Fluoride.Investigational
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.Approved
MethyclothiazidePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisolone.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisolone.Approved
MethyltestosteronePrednisolone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Prednisolone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Prednisolone.Experimental
MetoclopramideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Metoclopramide.Approved, Investigational
MetolazonePrednisolone may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Prednisolone.Experimental
MifepristoneThe serum concentration of Prednisolone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednisolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisolone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Prednisolone.Experimental
MoxestrolThe serum concentration of Prednisolone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nalidixic Acid.Approved, Investigational
NandrolonePrednisolone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoatePrednisolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednisolone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisolone.Approved
NetupitantThe serum concentration of Prednisolone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Prednisolone can be decreased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Prednisolone.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Prednisolone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisolone.Approved
NilotinibThe metabolism of Prednisolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisolone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Prednisolone can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Prednisolone.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prednisolone.Vet Approved
OsimertinibThe serum concentration of Prednisolone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Prednisolone.Approved
OxandrolonePrednisolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Oxolinic acid.Experimental
OxymetholonePrednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisolone.Approved, Vet Approved
PalbociclibThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Prednisolone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisolone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Prednisolone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Prednisolone.Approved, Investigational, Vet Approved, Withdrawn
PeruvosidePeruvoside may decrease the cardiotoxic activities of Prednisolone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisolone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Prednisolone.Approved, Investigational
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pipemidic acid.Experimental
PiretanidePrednisolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisolone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisolone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Prednisolone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Prednisolone.Approved
Polyestradiol phosphateThe serum concentration of Prednisolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePrednisolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisolone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prednisolone.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Prednisolone.Approved
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Prednisolone.Experimental
PromestrieneThe serum concentration of Prednisolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisolone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Prednisolone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Prednisolone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Prednisolone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prednisolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Prednisolone can be increased when it is combined with Quinestrol.Approved
QuinethazonePrednisolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Prednisolone.Approved
RanolazineThe serum concentration of Prednisolone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednisolone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Prednisolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prednisolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Prednisolone.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisolone.Approved
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone.Approved
SecoisolariciresinolThe serum concentration of Prednisolone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Prednisolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisolone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prednisolone.Investigational
SildenafilThe metabolism of Prednisolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prednisolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prednisolone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Prednisolone.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Prednisolone can be decreased when combined with Sodium bicarbonate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Prednisolone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Prednisolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prednisolone.Investigational
St. John's WortThe serum concentration of Prednisolone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololPrednisolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Prednisolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednisolone.Approved
SulfisoxazoleThe metabolism of Prednisolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednisolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisolone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Prednisolone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prednisolone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisolone.Approved, Withdrawn
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Prednisolone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prednisolone.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Prednisolone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone.Approved
TestosteronePrednisolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionatePrednisolone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Prednisolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisolone.Approved
TiboloneThe serum concentration of Prednisolone can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Prednisolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisolone.Investigational
TocilizumabThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisolone.Approved
TorasemidePrednisolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prednisolone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednisolone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisolone.Approved
TromethamineThe bioavailability of Prednisolone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Prednisolone.Approved, Investigational, Nutraceutical
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisolone.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Prednisolone is combined with Zoster vaccine.Approved
VenlafaxineThe metabolism of Prednisolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Prednisolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisolone.Approved, Investigational
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrednisolone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisolone.Approved, Investigational
ZeranolThe serum concentration of Prednisolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prednisolone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisolone.Withdrawn
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Gunther Bellmann, "Process for producing a sterile prednisolone gel." U.S. Patent US5811417, issued September 22, 1998.

US5811417
General References
Not Available
External Links
Human Metabolome Database
HMDB14998
KEGG Drug
D00472
KEGG Compound
C07369
PubChem Compound
5755
PubChem Substance
46504847
ChemSpider
5552
BindingDB
19190
ChEBI
8378
ChEMBL
CHEMBL131
Therapeutic Targets Database
DAP000419
PharmGKB
PA451096
IUPHAR
2866
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prednisolone
ATC Codes
S02BA03 — PrednisoloneD07AA03 — PrednisoloneR01AD52 — Prednisolone, combinationsA07EA01 — PrednisoloneV03AB05 — Prednisolone and promethazineD07XA02 — PrednisoloneC05AA04 — PrednisoloneD07CA03 — Prednisolone and antibioticsS01CB02 — PrednisoloneS01CA02 — Prednisolone and antiinfectivesA01AC54 — Prednisolone, combinationsS03BA02 — PrednisoloneS02CA01 — Prednisolone and antiinfectivesR01AD02 — PrednisoloneS03CA02 — Prednisolone and antiinfectivesS01BA04 — PrednisoloneD07BA01 — Prednisolone and antisepticsH02AB06 — PrednisoloneS01BB02 — Prednisolone and mydriatics
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (101 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnDiagnosticSevere Alcoholic Hepatitis1
1Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics / Pharmacokinetics / Rheumatoid Arthritis / Safety / Tolerability1
1CompletedBasic ScienceHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedBasic ScienceImmunoscience1
1CompletedOtherInflammatory Reaction1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentRheumatoid Arthritis1
1RecruitingPreventionEsophageal Anastomotic Stricture1
1RecruitingTreatmentStatus Asthmaticus1
1TerminatedTreatmentAsthma Bronchial1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentProstate Cancer1
1, 2CompletedBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentLipomas1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentNon-Infectious Anterior Uveitis1
1, 2CompletedTreatmentProstate Cancer1
1, 2RecruitingTreatmentDiffuse B-Cell Lymphoma1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingSupportive CareMalignant Tumor of Breast / Neoplasm of the Breast / Oral Mucositis / Vesicular Stomatitis1
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2CompletedNot AvailableAsthma Bronchial1
2CompletedBasic ScienceCataracts1
2CompletedBasic ScienceWhole Body Catabolisme Induced by Glucocorticoids1
2CompletedPreventionBullous Keratopathy / Fuchs' Dystrophy1
2CompletedPreventionMacular Edema (ME)1
2CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAlcoholic Hepatitis (AH)1
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConnective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity1
2CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentHIV Disease Progression1
2CompletedTreatmentHansen's Disease2
2CompletedTreatmentHormone Refractory / Metastatic / Prostate Cancer1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMacular Edema After Cataract Surgery in Patients With Diabetes Mellitus1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMetastatic Cancers / Prostate Cancer1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentNon-Infectious Anterior Uveitis1
2CompletedTreatmentProstate Cancer2
2CompletedTreatmentRheumatoid Arthritis4
2Enrolling by InvitationPreventionIritis1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentCognitive Change / Immune Suppression / Psychosis / Schizophrenia and Related Disorders1
2RecruitingTreatmentAcute Interstitial Nephritis1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAlcoholic Hepatitis (AH)1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentCerebral Radiation Necrosis1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentIatrogenic Cushing's Disease1
2RecruitingTreatmentKaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2SuspendedTreatmentAllergic Alveolitis1
2TerminatedBasic ScienceDependence, Cocaine / Opioid Dependence1
2TerminatedTreatmentHemangiomas2
2TerminatedTreatmentHemangiomas of Infancy1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentChronic Renal Insufficiency / Transplantation, Liver1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentStomatitis, Aphthous1
2WithdrawnTreatmentLPL Deficiency1
2, 3Active Not RecruitingTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedDiagnosticRheumatoid Arthritis1
2, 3CompletedTreatmentAspergillosis, Allergic Bronchopulmonary2
2, 3CompletedTreatmentGluten Enteropathy1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentInfertilities1
2, 3CompletedTreatmentPolymyalgia Rheumatica1
2, 3Not Yet RecruitingTreatmentIgA Nephropathy1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentProstate Cancer1
2, 3Unknown StatusTreatmentAnkylosing Spondylitis (AS)1
3Active Not RecruitingTreatmentAsthma Bronchial1
3Active Not RecruitingTreatmentChurg-Strauss Syndrome (CSS)1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentProgression of Rheumatoid Arthritis1
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedNot AvailableUveitis1
3CompletedBasic ScienceCataracts1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3CompletedTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAnemia, Hemolytic, Autoimmune1
3CompletedTreatmentAsthma Bronchial2
3CompletedTreatmentAsthma Bronchial / Wheezing1
3CompletedTreatmentCancers / Carcinoma NOS / Malignant Ascites / Neoplasms1
3CompletedTreatmentCataracts1
3CompletedTreatmentCataracts / Inflammatory Reaction1
3CompletedTreatmentCataracts / Non-Proliferative Diabetic Retinopathy2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentEndogenous Anterior Uveitis1
3CompletedTreatmentEye Infections / Postoperative Complications1
3CompletedTreatmentGlomerulonephritis, Membranous1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentGlomerulonephritis, Membranous / Nephritis, Lupus1
3CompletedTreatmentHeadaches1
3CompletedTreatmentHemangiomas1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP)1
3CompletedTreatmentInfantile Spasms (IS) / West Syndrome1
3CompletedTreatmentInfection and Inflammation After Refractive Surgery (Lasik)1
3CompletedTreatmentLeukemias3
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMalignant Lymphomas4
3CompletedTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentMyasthenia Gravis1
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentTuberculous Pericarditis1
3CompletedTreatmentUlcerative Colitis (UC)1
3Not Yet RecruitingTreatmentArterial Ischemic Stroke1
3Not Yet RecruitingTreatmentGlomerulonephritis minimal lesion / Glomerulosclerosis, Focal Segmental / Idiopathic Nephrotic Syndrome1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1
3Not Yet RecruitingTreatmentInfantile Spasms (IS)1
3RecruitingPreventionAcute Urinary Tract Infection / Urinary Tract Infections (UTIs)1
3RecruitingSupportive CarePulpitis dental1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3RecruitingTreatmentAnterior Uveitis (AU)1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentGraves Diseases / Hyperthyroidism1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentImmuoglobulin / Mucocutaneous Lymph Node Syndrome / Steroid1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3SuspendedTreatmentSystemic Lupus Erythematosus, Lupus Nephritis1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentDiscal Sciatica1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentPemphigus1
3TerminatedTreatmentUlcerative Colitis (UC)1
3Unknown StatusTreatmentAlcoholic Hepatitis (AH)1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Contact / Psoriasis / Seborrheic Dermatitis1
3Unknown StatusTreatmentBiliary Atresia1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentInfantile Spasms (IS)1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentMalignant Lymphomas4
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3Unknown StatusTreatmentRheumatoid Arthritis1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3WithdrawnTreatmentNephritis, Lupus1
4Active Not RecruitingTreatmentConjunctivitis, Giant Papillary / Conjunctivitis, Seasonal Allergic / Inflammatory Reaction1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4Active Not RecruitingTreatmentProstate Cancer1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4Active Not RecruitingTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableMacula Thickening1
4CompletedPreventionCataracts1
4CompletedPreventionChronic Allergic Conjunctivitis1
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedPreventionCorneal Edema / Fuchs' Dystrophy1
4CompletedPreventionRenal Transplanted Recipients1
4CompletedPreventionTracheal Stenosis1
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia3
4CompletedTreatmentAsthma Bronchial3
4CompletedTreatmentAtopic Dermatitis (AD)1
4CompletedTreatmentBell's Palsy1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCataract operation1
4CompletedTreatmentCataracts2
4CompletedTreatmentCataracts / Corneal Edema / Retinal Structural Change, Deposit and Degeneration / Visual Acuity Reduced Transiently1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentCataracts / Glaucoma1
4CompletedTreatmentChronic Diseases / Idiopathic eosinophilic pneumonias1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentGlaucoma1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHemangiomas1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMCNS / Minimal Change Nephrotic Syndrome (MCNS)1
4CompletedTreatmentMeibomian Gland Dysfunction (MGD)1
4CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
4CompletedTreatmentOptic Disk / Regional Blood Flow1
4CompletedTreatmentOral Lichen Planus1
4CompletedTreatmentPain1
4CompletedTreatmentPolyps, Nasal1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPulpitis dental1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSepsis1
4Enrolling by InvitationTreatmentCrohn's Disease (CD)1
4Not Yet RecruitingTreatmentCystoid Macular Edema / Macular Edema (ME) / Uveitis1
4Not Yet RecruitingTreatmentGlomerulonephritis minimal lesion1
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingDiagnosticCoughing1
4RecruitingPreventionEsophageal Strictures / Esophagus, Barrett1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
4RecruitingTreatmentBlood Eosinophil Count / Chronic Obstructive Pulmonary Disease (COPD) / Glucocorticoid therapy / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
4RecruitingTreatmentChoroidal Effusions / Glaucoma1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentEpilepsy, Unspecified, Intractable1
4RecruitingTreatmentFulminant Hepatic Failure1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentGlomerulonephritis minimal lesion2
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentImmunoglobulin G4 Related Sclerosing Disease1
4RecruitingTreatmentInfertilities / Polycystic Ovarian Syndrome1
4RecruitingTreatmentMalignant Lymphomas1
4RecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
4RecruitingTreatmentOphthalmopathy, Thyroid-Associated1
4RecruitingTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4RecruitingTreatmentRecurrent IgA Nephropathy1
4RecruitingTreatmentRheumatoid Arthritis2
4RecruitingTreatmentSarcoidosis1
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4TerminatedTreatmentImmune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy1
4TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4Unknown StatusPreventionCataract operation / Pseudophakia1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentCataracts1
4Unknown StatusTreatmentChronic Hepatitis B Infection1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentDisorder Related to Renal Transplantation1
4Unknown StatusTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableCompletedNot AvailableHemangiomas1
Not AvailableCompletedBasic ScienceElectroretinography1
Not AvailableCompletedPreventionBeta-cell Function / Diabetes Mellitus (DM) / Glucocorticoid-induced Diabetes / Steroid Diabetes1
Not AvailableCompletedPreventionEpiretinal Membrane1
Not AvailableCompletedPreventionPatients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy1
Not AvailableCompletedTreatmentBiliary Atresia1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentCorneal Neovascularization1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentGlucocorticoid-induced Beta-cell Dysfunction / Glucocorticoid-induced Glucometabolic Abnormalities1
Not AvailableCompletedTreatmentGlucose tolerance impaired / Hyperglycemias / Insulin Resistance1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentModerate to Severe Atopic Dermatitis1
Not AvailableCompletedTreatmentReproductive Sterility1
Not AvailableCompletedTreatmentScleral Buckling1
Not AvailableCompletedTreatmentTuberculous Pleurisy1
Not AvailableNot Yet RecruitingTreatmentAllergies / Urticarias1
Not AvailableNot Yet RecruitingTreatmentTonsillectomy1
Not AvailableRecruitingNot AvailableDegeneration / Ectasia / Keratoconus2
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingHealth Services ResearchHypospadias1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableTerminatedNot AvailableProstatic Neoplasms1
Not AvailableTerminatedTreatmentDrug Induced Liver Injury1
Not AvailableTerminatedTreatmentOpen Angle Glaucoma (OAG)1
Not AvailableUnknown StatusNot AvailableAsthma Exacerbations1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusPreventionAsthma Bronchial1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentBehcet's Syndrome / Uveal Disease1
Not AvailableUnknown StatusTreatmentBell's Palsy1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentMalignant Lymphomas3
Not AvailableWithdrawnNot AvailableLeukemias1
Not AvailableWithdrawnTreatmentBronchiolitis1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
OintmentOphthalmic
Suspension / dropsOphthalmic
Solution / dropsOphthalmic
OintmentOphthalmic; Topical
SuspensionOral15 mg/5mL
LiquidOphthalmic10 mg
SolutionOphthalmic1 %
LiquidOphthalmic.125 %
LiquidOphthalmic1.25 mg
SuspensionOphthalmic
SolutionOral10 mg/5mL
TabletOral5 mg/1
TabletOral5 mg/5mg
Solution / dropsOphthalmic0.5 %
TabletOral5 mg
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
LiquidOral5 mg
SolutionOral5 mg
Suspension / dropsOphthalmic1.2 mg/mL
Solution / dropsOphthalmic0.12 %
SyrupOral15 mg/5mL
SyrupOral5 mg/5mL
SuspensionOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/1
SolutionOral15 mg/5mL
SolutionOral5 mg/5mL
Solution / dropsOphthalmic10 mg/mL
SolutionOral25 mg/5mL
Liquid; solution / dropsOphthalmic1 %
SuspensionOphthalmic0.12 %
SuspensionOphthalmic1 %
SolutionOphthalmic
LiquidOphthalmic
SolutionOral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US6740341No1999-11-242019-11-24Us
US7799331No2008-10-112028-10-11Us
US6071523No1998-06-032018-06-03Us
US6399079No1998-06-032018-06-03Us
US5881926No1996-03-162016-03-16Us
US6656482No1998-06-032018-06-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-1910000000-2f59b266e7257ff0e7ad
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0019000000-34782b355045c38d0504
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-4a00ac3c2f4930e108cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0689000000-b0eaba9949ae34d0e571
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-0a92fbafb31c0170151c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-856481c7f4d3a6d1ac63
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-813955b7791f046a3a67
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-c70a1009bba6e4f3a2c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0009000000-e4bce0d078573494d8cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006w-0905000000-94eb00e6ffa4c56ac51b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-7797dc6be351391cf57a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-d156992d517e46c9575d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00r2-0910000000-598b90f7f0f7ba4e13eb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-eed30fed077e1dfffd3b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-0af4f657def15fe9274e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1920000000-5811b59a6f57222762d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06xw-2910000000-84fec77617e1b7a1648b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dl-0596000000-e0abadaf09054d046b08
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xu-0595000000-4f8d30df506ea649fc04
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-1986000000-d088900fa4c56b9ff51d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0900000000-01f9c0e6f14839685506

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
show 4 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 15 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:8378) / Pregnane and derivatives [Fig] (C07369) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030179)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18